RENEW Scleroderma: A Peer-Mentored, Web Intervention for Resilience-based, Energy Management to Enhance Wellbeing and Fatigue (RENEW)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Shannen Bolde
- Phone Number: 734-615-8543
- Email: sbolde@umich.edu
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Have a diagnosis of Systemic Sclerosis (SSc), any subtype
- Report a mean score of at least 4 on the Fatigue Severity Scale; potential mean range 1-9
- Have access to a computer and an internet connection
- Are able to speak and read English.
Exclusion Criteria:
- Currently undergoing structured rehabilitation or psychological treatment.
- Other issues that preclude meaningful participation in study procedures (e.g. concurrent or complex medical issues, inability to access RENEW intervention, etc.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Resilience-based, Energy Management to Enhance Wellbeing and Fatigue (RENEW)
RENEW was created by researchers, doctors, and patients with scleroderma.
It is a web-based peer-led program to help manage energy and symptoms in people who have scleroderma.
|
RENEW is a 12-week, peer-led, web-based program to help people with scleroderma learn skills that can be used to manage disease symptoms and improve well-being.
|
|
No Intervention: Waitlist
Participants will be asked about changes in health status, and use of any new treatments or services at 6 and 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Fatigue
Time Frame: Up to 12 weeks
|
Fatigue is measured by The Functional Assessment of Chronic Illness Therapy (FACIT) -Fatigue 13a.
FACIT is a questionnaire with 13 questions and a score ranging from 13-65.
Higher scores indicate greater fatigue.
|
Up to 12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Pain Interference
Time Frame: Up to 12 weeks
|
Pain interference is measured by Patient-Reported Outcomes Measurement Information System (PROMIS) pain interference 4a scale Pain Interference 4a will assess self-reported consequences of pain with 4 questions ranked on a 5-point scale, from "not at all" to "very much".
The minimum score is 4 and the maximum score is 20.
Lower scores suggest less pain interference.
|
Up to 12 weeks
|
|
Change in Resilience
Time Frame: Up to 12 weeks
|
Resilience is measured by Connor-Davidson Resilience Scale 10 (CD-RISC-10).
It is a 10 item self-report rating scale 0 (not true at all) to 4 (true nearly all the time).
The overall score range from 0 (no resilience) to 40 (High Resilience).
|
Up to 12 weeks
|
|
Change in Depressive symptoms
Time Frame: Up to 12 weeks
|
Depressive symptoms are measured by PROMIS depression 4a assesses self-reported negative mood (e.g., sadness), views of self (e.g., worthlessness), social cognition (e.g., loneliness), and decreased positive affect and engagement.
Items are all answered on a 5-point scale from 1=Never to 5=Always.
Scores can range from 0 meaning no anxiety/depression to 40 meaning high
|
Up to 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Susan Murphy, University of Michigan
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HUM00195121
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.